目的：观察糖尿病黄斑水肿采取玻璃体腔注射抗血管内皮生长因子药物联合激光光凝的疗效及安全性。

方法：回顾性分析86例102眼糖尿病黄斑水肿患者临床资料，随机分为2组，对照组采取激光光凝治疗； 观察组于对照组基础上加用璃体腔注射抗血管内皮生长因子治疗：麻醉后行常规消毒铺巾，角膜缘后3.5～4mm进针，缓慢注射康栢西普0.05mL，并压迫、包眼。比较两组疗效，并统计两组不良反应。

结果：治疗后两组视力均改善，且观察组视力情况优于对照组(P<0.05)； 治疗后观察组总有效率90.9%，高于对照组76.6%(P<0.05)； 两组治疗后黄斑中心视网膜厚度(CRT)、黄斑总体积(TMV)水平均降低，且观察组治疗后CRT、TMV水平均低于对照组(P<0.05)； 两组不良反应比较差异无统计学意义(P>0.05)。

结论：糖尿病黄斑水肿采用玻璃体腔注射抗血管内皮生长因子药物联合激光光凝治疗疗效较佳，可降低黄斑中心视网膜厚度、距黄斑中心凹6mm范围内黄斑总体积，且应用安全。

METHODS: Retrospective analysis on clinical data of 86 patients(102 eyes)with diabetic macular edema and they were divided into 2 groups randomly. The control group adopted laser photocoagulation treatment; observation group accepted anti-VEGF treated basis on control group(Conbercept 0.05mL). We compared the effects and the adverse reactions of the two groups.

RESULTS: After treatment, visual acuity of the two both increased; the observation group's situation was better than the control group(P<0.05). After treatment, the total efficiency rate of the observation group was 90.9%, which was higher than that of the control group of(76.6%, P<0.05). After treatment, the macular retinal thickness(CRT)and total macular volume(TMV)levels of the two group decreased, and the CRT and TMV of observation group were lower than the control group(P<0.05); there was no significant difference between the two groups on adverse reactions(P>0.05).

CONCLUSION: The efficacy on diabetic macular edema by intravitreal injection of anti VEGF drug combined with laser photocoagulation is better, can reduce the CRT, TMV in the range of 6mm, and application security is good.